Table 3.

Unadjusted total and disease-specific spending for the combined intervention and post-intervention phases (cumulative follow-up) of the Women’s Health Initiative hormone therapy clinical trials (2016 USD)

	With Any Spending (%)		Mean Spending
	CEE+MPA	Placebo	CEE +MPA	Placebo	% Diff	P-value
	(n=2304)	(n=2253)
Total spending	98.3	97.5	$191,313	$190,195	0.6	0.36
Global index spending	43.3	42.7	11,801	13,008	−9.3	0.72
Stroke	21.7	21.3	2,407	2,588	−7.0	0.54
Coronary heart disease	9.6	10.3	1,612	1,467	9.9	0.51
Pulmonary embolism	4.3	4.1	535	313	7.1	0.63
Invasive breast cancer	8.4	6.7	4,115	3,329	23.6	0.028
Endometrial cancer	1.3	2.0	332	948	−65.0	0.10
Colorectal cancer	3.7	4.3	1,036	2,060	−49.7	0.28
Hip fracture	9.5	10.6	1,761	2,299	−23.4	0.19
	CEE-Alone (n=1533)	Placebo (n=1574)	CEE-Alone	Placebo	% Dif	P-value
Total spending	98.5	97.6	$221,628	$214,830	3.2	0.40
Global index spending	44.3	44.8	12,885	11,140	15.7	0.87
Stroke	24.6	24.3	2,791	3,029	−7.9	0.97
Coronary heart disease	12.2	10.2	2,215	1,448	52.9	0.06
Pulmonary embolism	4.6	5.2	312	387	−19.3	0.44
Invasive breast cancer	6.8	7.6	4,133	2,957	39.8	0.39
Colorectal cancer	4.4	4.5	1,448	1,304	11.0	0.99
Hip fracture	9.7	10.4	1,983	2,013	−1.5	0.60